This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Earl, P. L.
Right arrow Articles by Moss, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Earl, P. L.
Right arrow Articles by Moss, B.

 Previous Article  |  Next Article 

Journal of Virology, October 2003, p. 10684-10688, Vol. 77, No. 19
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.19.10684-10688.2003

Development and Use of a Vaccinia Virus Neutralization Assay Based on Flow Cytometric Detection of Green Fluorescent Protein

Patricia L. Earl, Jeffrey L. Americo, and Bernard Moss*

Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-0445

Received 20 May 2003/ Accepted 9 July 2003

A rapid and sensitive neutralization assay is required to evaluate alternative smallpox vaccines. Here we describe the development and use of a 96-well plate, semi-automated, flow cytometric assay that uses a recombinant vaccinia virus expressing enhanced green fluorescent protein and which would be applicable to other viruses.

* Corresponding author. Mailing address: NIH, 4 Center Dr., MSC 0445, Bethesda, MD 20892-0445. Phone: (301) 496-9869. Fax: (301) 480-1147. E-mail: bmoss{at}nih.gov.

Journal of Virology, October 2003, p. 10684-10688, Vol. 77, No. 19
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.19.10684-10688.2003




This article has been cited by other articles:

  • Kennedy, R., Pankratz, V. S., Swanson, E., Watson, D., Golding, H., Poland, G. A. (2009). Statistical Approach To Estimate Vaccinia-Specific Neutralizing Antibody Titers Using a High-Throughput Assay. CVI 16: 1105-1112 [Abstract] [Full Text]  
  • Wagenaar, T. R., Moss, B. (2009). Expression of the A56 and K2 Proteins Is Sufficient To Inhibit Vaccinia Virus Entry and Cell Fusion. J. Virol. 83: 1546-1554 [Abstract] [Full Text]  
  • Fogg, C. N., Americo, J. L., Earl, P. L., Resch, W., Aldaz-Carroll, L., Eisenberg, R. J., Cohen, G. H., Moss, B. (2008). Disparity between Levels of In Vitro Neutralization of Vaccinia Virus by Antibody to the A27 Protein and Protection of Mice against Intranasal Challenge. J. Virol. 82: 8022-8029 [Abstract] [Full Text]  
  • Earl, P. L., Americo, J. L., Wyatt, L. S., Espenshade, O., Bassler, J., Gong, K., Lin, S., Peters, E., Rhodes, L. Jr, Spano, Y. E., Silvera, P. M., Moss, B. (2008). Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc. Natl. Acad. Sci. USA 105: 10889-10894 [Abstract] [Full Text]  
  • Davies, D. H., Wyatt, L. S., Newman, F. K., Earl, P. L., Chun, S., Hernandez, J. E., Molina, D. M., Hirst, S., Moss, B., Frey, S. E., Felgner, P. L. (2008). Antibody Profiling by Proteome Microarray Reveals the Immunogenicity of the Attenuated Smallpox Vaccine Modified Vaccinia Virus Ankara Is Comparable to That of Dryvax. J. Virol. 82: 652-663 [Abstract] [Full Text]  
  • Belyakov, I. M., Isakov, D., Zhu, Q., Dzutsev, A., Klinman, D., Berzofsky, J. A. (2006). Enhancement of CD8+ T Cell Immunity in the Lung by CpG Oligodeoxynucleotides Increases Protective Efficacy of a Modified Vaccinia Ankara Vaccine against Lethal Poxvirus Infection Even in a CD4-Deficient Host. J. Immunol. 177: 6336-6343 [Abstract] [Full Text]  
  • Brown, E., Senkevich, T. G., Moss, B. (2006). Vaccinia Virus F9 Virion Membrane Protein Is Required for Entry but Not Virus Assembly, in Contrast to the Related L1 Protein. J. Virol. 80: 9455-9464 [Abstract] [Full Text]  
  • Townsley, A. C., Weisberg, A. S., Wagenaar, T. R., Moss, B. (2006). Vaccinia Virus Entry into Cells via a Low-pH-Dependent Endosomal Pathway.. J. Virol. 80: 8899-8908 [Abstract] [Full Text]  
  • Chen, Z., Earl, P., Americo, J., Damon, I., Smith, S. K., Zhou, Y.-H., Yu, F., Sebrell, A., Emerson, S., Cohen, G., Eisenberg, R. J., Svitel, J., Schuck, P., Satterfield, W., Moss, B., Purcell, R. (2006). Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc. Natl. Acad. Sci. USA 103: 1882-1887 [Abstract] [Full Text]  
  • Lustig, S., Fogg, C., Whitbeck, J. C., Eisenberg, R. J., Cohen, G. H., Moss, B. (2005). Combinations of Polyclonal or Monoclonal Antibodies to Proteins of the Outer Membranes of the Two Infectious Forms of Vaccinia Virus Protect Mice against a Lethal Respiratory Challenge. J. Virol. 79: 13454-13462 [Abstract] [Full Text]  
  • Morikawa, S., Sakiyama, T., Hasegawa, H., Saijo, M., Maeda, A., Kurane, I., Maeno, G., Kimura, J., Hirama, C., Yoshida, T., Asahi-Ozaki, Y., Sata, T., Kurata, T., Kojima, A. (2005). An Attenuated LC16m8 Smallpox Vaccine: Analysis of Full-Genome Sequence and Induction of Immune Protection. J. Virol. 79: 11873-11891 [Abstract] [Full Text]  
  • Fogg, C., Lustig, S., Whitbeck, J. C., Eisenberg, R. J., Cohen, G. H., Moss, B. (2004). Protective Immunity to Vaccinia Virus Induced by Vaccination with Multiple Recombinant Outer Membrane Proteins of Intracellular and Extracellular Virions. J. Virol. 78: 10230-10237 [Abstract] [Full Text]  
  • Wyatt, L. S., Earl, P. L., Eller, L. A., Moss, B. (2004). Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc. Natl. Acad. Sci. USA 101: 4590-4595 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»